RxDoctor Payments DataLook up a doctor →

Marlee Booty, NP

Acute Care · McComb, MSNPI 1306445069

Payments from drug & device makers

$7,520in general payments, 2019–2025

Across 366 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$580
  • Pfizer$506
  • Merck$475
  • AstraZeneca$456
  • Incyte Corporation$409
  • Novartis$369
  • plus $5K from 54 others

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)29$580
Pfizer27$506
Merck22$475
AstraZeneca23$456
Incyte Corporation19$409
Novartis21$369
Astellas Pharma US Inc10$269
Genmab U.S., Inc.7$240
Beigene USA, Inc.5$224
Pharmacosmos Therapeutics Inc.13$212
Gilead(2 entities)8$212
Bayer12$207
Bristol Myers Squibb11$202
AVEO Pharmaceuticals, Inc.6$191
E.r. Squibb & Sons, L.L.C.10$171
Genentech USA, Inc.7$157
Array Biopharma Inc7$150
Adaptive Biotechnologies Corporation6$143
Regeneron Healthcare Solutions, Inc.6$121
Puma Biotechnology, Inc.7$120
Eisai Inc.7$118
Jazz Pharmaceuticals Inc.5$116
Lilly USA, LLC5$101
Sanofi-aventis U.S. LLC1$99
Ipsen Biopharmaceuticals, Inc4$94
Sanofi5$88
GSK5$88
AbbVie5$87
Daiichi Sankyo Inc.4$85
Takeda Pharmaceuticals U.S.A., Inc.4$83
Seagen Inc.6$82
Beone Medicines USA, Inc.4$80
Exelixis Inc.4$71
Stemline Therapeutics Inc.3$71
Karyopharm Therapeutics Inc.3$60
Morphosys, US Inc.3$57
Pharmaessentia USA Corporation2$53
Boehringer Ingelheim3$48
Geron Corporation2$44
Dendreon Pharmaceuticals LLC2$44
Coherus Oncology, Inc.2$39
Alnylam Pharmaceuticals Inc.2$36
Amgen2$35
Mirati Therapeutics, Inc.2$34
Cumberland Pharmaceuticals, Inc.2$32
Spectrum Pharmaceuticals Inc.2$32
ADC Therapeutics America, Inc.2$31
Shield Therapeutics Inc2$31
Progenics Pharmaceuticals, Inc.1$31
Tolmar, Inc.2$29
EMD Serono, Inc.2$27
Pharmaand GmbH4$24
Servier Pharmaceuticals LLC1$23
Rigel Pharmaceuticals, Inc.1$21
Sobi, Inc1$21
Azurity Pharmaceuticals, Inc.1$20
Celltrion USA Inc.1$19
Fresenius Kabi USA, LLC1$19
Caris MPI, Inc.1$16
Ferring Pharmaceuticals Inc.1$14

How this compares

$7,520 in reported general payments places this provider in the 90th percentile of 223 acute care providers in Mississippi.

See all acute care providers in Mississippi

Medicare billing

Part B allowed, 2024
$49,303
Medicare patients
320
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in McComb

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →